PMID- 25033694
OWN - NLM
STAT- MEDLINE
DCOM- 20140814
LR  - 20151119
IS  - 0507-3758 (Print)
IS  - 0507-3758 (Linking)
VI  - 60
IP  - 3
DP  - 2014
TI  - [Fallopian tube carcinoma: clinical and morphological features, analysis of 69 
      cases].
PG  - 375-8
AB  - Primary fallopian tube carcinoma (PFTC) is a rare gynecological malignancy 
      accounting 0.14-1.8% cases. The purpose of the study was to assess clinical, 
      morphological and immunohistochemical features of PFTC. All the cases of PFTC 
      were detected during 1980-2005. 31 cases of PFTC were analyzed as to Ki-67, HER-2 
      expression, estrogen receptors (ER), progesterone receptors (PR), grade and 
      stage. 69 cases of PFTC were detected with an average age of 55, 6 years (range 
      21-73 years). Stage I detected in 34.2% cases, Stages II and III--32.8%, Ca in 
      situ--10%. Among 31 patients ER were positive in 75% (n = 23), PR were positive 
      in 46% (n = 14): ER+PR+ in 12 (38%) cases, ER+PR- in 11 (36%) cases, ER-PR+ in 2 
      (6%) cases, ER-PR- in 6 (19.4%) cases. Only 2 cases were HER-2 positive with 
      ER+PR+ and ER-PR- status. Ki-67 labeling index (LI, %) values ranged from 15 to 
      95% (median 60) with average rate 58.03% +/- 4.08. Ki-67 LI values > or = 60% 
      were graded as high and < 60% as low. We did not find any significant differences 
      in Ki-67 LI values among tumors of various Receptor Status. However Ki-67 L1 > 
      60% was associated with poor 5-year survival (14%), vs 75% in Ki-67 L1 < 60%. 
      Primary fallopian tube carcinoma is mainly HER-2 negative, receptor positive in 
      79.6%. Ki-67 rate is irrespective of ER PR status. However the level of Ki-67 (> 
      60%) was a significant survival prognostic factor.
FAU - Ul'rikh, E A
AU  - Ul'rikh EA
FAU - Papunidi, M D
AU  - Papunidi MD
FAU - Urmancheeva, A F
AU  - Urmancheeva AF
FAU - Matsko, D E
AU  - Matsko DE
LA  - rus
PT  - English Abstract
PT  - Journal Article
PL  - Russia (Federation)
TA  - Vopr Onkol
JT  - Voprosy onkologii
JID - 0413775
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Ki-67 Antigen)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*analysis
MH  - Fallopian Tube Neoplasms/*chemistry/*diagnosis/pathology
MH  - Female
MH  - Humans
MH  - Ki-67 Antigen/analysis
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Receptor, ErbB-2/analysis
MH  - Receptors, Estrogen/analysis
MH  - Receptors, Progesterone/analysis
MH  - Retrospective Studies
MH  - Russia/epidemiology
MH  - Survival Analysis
EDAT- 2014/07/19 06:00
MHDA- 2014/08/15 06:00
CRDT- 2014/07/19 06:00
PHST- 2014/07/19 06:00 [entrez]
PHST- 2014/07/19 06:00 [pubmed]
PHST- 2014/08/15 06:00 [medline]
PST - ppublish
SO  - Vopr Onkol. 2014;60(3):375-8.